High Costs of FDA Approval for Formerly Unapproved Marketed Drugs

JAMA. 2017 Dec 12;318(22):2181-2182. doi: 10.1001/jama.2017.16481.

MeSH terms

  • Drug Approval*
  • Drug Costs*
  • Drug Discovery
  • Drugs, Generic / economics*
  • Economic Competition
  • Government Regulation*
  • Infusions, Intravenous
  • Marketing*
  • Prescription Drugs / economics*
  • United States
  • United States Food and Drug Administration*
  • Vasopressins / administration & dosage
  • Vasopressins / economics

Substances

  • Drugs, Generic
  • Prescription Drugs
  • Vasopressins